CSIMarket
 
Vaccinex Inc   (NONE: VCNX)
Other Ticker:  
 
 
Price: $0.7970 $-0.08 -9.226%
Day's High: $0.797 Week Perf: 10.66 %
Day's Low: $ 0.73 30 Day Perf: -18.67 %
Volume (M): 1 52 Wk High: $ 8.90
Volume (M$): $ 0 52 Wk Avg: $3.05
Open: $0.73 52 Wk Low: $0.25



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 2
 Employees 71
 Revenues (TTM) (Millions $) -1
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Vaccinex Inc
Vaccinex Inc is a clinical-stage biotechnology company that focuses on the discovery and development of novel therapeutic antibodies for the treatment of cancer and neurodegenerative diseases. The company uses its proprietary antibody discovery platform, called ActivMAb, to identify and develop antibodies that can selectively target and neutralize specific disease-causing proteins.
Vaccinex has a particular expertise in the development of antibodies that target the CXCL13 chemokine, which is found in high levels in the tumor microenvironment in various cancers. By targeting CXCL13, Vaccinex aims to disrupt the tumor microenvironment and enhance the body's immune response to fight cancer.
In addition to its cancer programs, Vaccinex is also exploring the therapeutic potential of its antibodies in neurodegenerative diseases such as Huntington's disease and Alzheimer's disease. The company's pipeline includes several antibody candidates in various stages of preclinical and clinical development.
Vaccinex has ongoing collaborations with pharmaceutical companies and research institutions to further advance its antibody programs. The company's goal is to develop innovative antibody-based therapies that can improve patient outcomes and address significant unmet medical needs.


   Company Address: 1895 Mount Hope Avenue Rochester 14620 NY
   Company Phone Number: 271-2700   Stock Exchange / Ticker: NONE VCNX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV     
BMY     
HCM     
LLY     
PFE     
REGN     
• View Complete Report
   



Clinical Study

Pepinemab A Dual Role in Oncology and Neurology - Exploring Vaccinexs Promising Clinical Findings

Published Tue, May 27 2025 12:57 PM UTC

In the evolving landscape of biopharmaceutical innovation, Vaccinex Inc. has emerged as a key player with its investigational drug pepinemab, a monoclonal antibody showing great potential in treating both head and neck cancer as well as Alzheimer s disease. The recent findings presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and the forthcoming up...

Partnership

Vaccinex Expands Horizons with Innovate ActivMAb Platform Pioneering Antibody Discovery in Cancer Immunotherapy

Published Thu, Nov 7 2024 1:30 PM UTC

In a robust display of innovation, Vaccinex Inc. has recently provided exciting updates on its proprietary ActivMAb platform, a revolutionary technology central to the discovery of therapeutic antibodies. Capitalizing on this cutting-edge capability, the company has secured multiple project deals that underscore its significant impact in the field of cancer immunotherapy. Fu...

Product Service News

Promising Biomarker and Cognitive Treatment Effects from Vaccinexs Pepinemab in Alzheimer?s Disease

Published Thu, Oct 31 2024 2:00 PM UTC

Overview of Pepinemab and its Phase 1b/2 TrialVaccinex Inc. recently presented new findings from the SIGNAL-AD Phase 1b/2 clinical trial of its investigational therapeutic agent, Pepinemab, at the Clinical Trials on Alzheimer?s Disease (CTAD) Conference held in Madrid, Spain. The trial primarily investigates the potential of Pepinemab in treating Mild Cognitive Impairment (...

Shares

Vaccinex Inc. Secures $6.2 Million from Warrant Exercises in Strategic Move to Bolster Operations Amid Q3 Challenges,

Published Wed, Sep 18 2024 12:30 PM UTC

Vaccinex Inc. Secures $6.2 Million from Warrant Exercises in Strategic Move to Bolster Operations Amid Q3 ChallengesRochester, N.Y. Sept. 18, 2024 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company specializing in innovative treatments for neurodegenerative diseases, announced today a significant financial milestone. The company has entered into definiti...

Clinical Study

Vaccinex Inc. Showcases Strategic Advancements in Alzheimers Disease Research and Financial Performance

Published Wed, Aug 14 2024 12:30 PM UTC

Vaccinex Inc., a biotechnology company dedicated to developing therapeutics for neurological diseases, has made significant strides in its clinical and financial arenas. Recently, the company provided updates on the SIGNAL-AD Phase 1b/2 trial of its investigational therapy, Pepinemab, in Alzheimer s disease, while also reporting impressive financial metrics in its third quar...







Vaccinex Inc's Segments

  Vaccinex Inc Outlook

On April 2 2024 the Vaccinex Inc provided following guidance

Vaccinex Inc. has released its financial results for 2023 and provided a comprehensive corporate update. The company anticipates unveiling the topline data from the randomized SIGNAL-AD study evaluating Pepinemab for Alzheimer's Disease in the third quarter of 2024. I...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com